文献速递脊柱关节炎

在依奇珠单抗三项随机临床试验中对外周型强直性脊柱炎疾病活动度评分的替代版本进行外部验证

External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

研究将COAST-V、COAST-W、COAST-X三项依奇珠单抗随机临床试验(主要终点16周)的放射学/非放射学中轴型脊柱关节炎患者汇总,共958例,评估替代ASDAS(altASDAS)的真实性与区分度。结果显示altASDAS与原始ASDAS一致性极好(ICC=0.99,κ=0.91),平均差异0.03(95%一致性界限-0.31~0.24),并能区分疾病活动状态、与ASDAS应答高度一致(κ MI=0.91,CII=0.93),结论为altASDAS已在外部队列中完成充分验证,可在患者总体评估不可用时使用。

要点

  • altASDAS与原始ASDAS一致性极好(ICC=0.99,κ=0.91),平均差异0.03(95%一致性界限-0.31~0.24)。
  • altASDAS可区分疾病活动状态,与ASDAS应答一致性κ在主要改善为0.91、临床重要改善为0.93。
  • altASDAS已在外部队列中完成充分验证,可在患者总体评估不可用时使用。

核心结论

  • altASDAS在外部队列中真实且具有区分度,已充分验证可在患者总体评估不可用时使用。

研究设计与样本

  • 汇总COAST-V、COAST-W、COAST-X三项依奇珠单抗随机临床试验(16周主要终点)的放射学/非放射学中轴型脊柱关节炎患者队列。
  • 共纳入958例患者,计算原始ASDAS(含患者总体评估的公式)与altASDAS。
  • 真实性通过ICC、加权κ、Bland-Altman图(平均差异及95%一致性界限)及Pearson相关性评估;区分度通过以夜间痛>6/10为外部锚区分高/低疾病活动度及与ASDAS在主要改善和临床重要改善上的κ一致性检验。

主要发现

  • altASDAS与ASDAS一致性极好(ICC=0.99,κ=0.91)。
  • altASDAS与ASDAS平均差异为0.03(95%一致性界限-0.31~0.24)。
  • altASDAS与相关构念的相关系数落在ASDAS与同一构念相关系数预设0.3宽度的范围内。
  • altASDAS可区分疾病活动状态,与ASDAS应答一致性κ在主要改善为0.91、临床重要改善为0.93。

关键数值与推荐

  • 真实性:与ASDAS的ICC=0.99,加权κ=0.91,平均差异0.03(95%一致性界限-0.31~0.24)。
  • 区分度:以夜间痛>6/10为外部锚可区分疾病活动状态,与ASDAS主要改善一致性κ=0.91、临床重要改善一致性κ=0.93。

临床怎么用

  • altASDAS已在外部队列中完成充分验证,可在患者总体评估不可用时使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The alternative ASDAS (altASDAS) is an index that can be used when patient global assessment is unavailable. Our aim was to test the truth and discrimination aspects according to OMERACT filter 2.0 of the altASDAS in an external cohort. METHODS: Cohorts from the COAST trials of ixekizumab (COAST-V, -W, -X; 16-week primary endpoint) enrolling radiographic/non-radiographic axial SpA patients were pooled. The ASDAS [original formula with patient global assessment (PGA)] and altASDAS were calculated. Truth was assessed by agreement with the continuous ASDAS [intraclass correlation coefficients (ICCs)] and ASDAS disease activity (DA) states (weighted κ), Bland-Altman plots [mean difference (MD) and 95% limits of agreement (LoA)] and Pearson's correlations between altASDAS/ASDAS and other constructs. Discrimination was tested by the ability of altASDAS to distinguish high/low DA according to nocturnal pain >6/10 as an external anchor and agreement (κ) with ASDAS in major improvement (MI) and clinically important improvement (CII). RESULTS: A total of 958 patients were included. For truth, agreement with ASDAS was very good (ICC = 0.99, κ = 0.91), MD with ASDAS was 0.03 (95% LoA -0.31-0.24) and correlation coefficients of altASDAS with related constructs were within a prespecified 0.3-wide band around those between ASDAS and the same construct. For discrimination, the altASDAS discriminated between DA states and agreed with ASDAS response (κ MI = 0.91, CII = 0.93). CONCLUSIONS: The altASDAS was truthful and discriminative in an external cohort and as such has been fully validated to be used in cases when PGA is unavailable.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ortolan A, Ramiro S, Ramonda R, et al. External validation of the alternative Ankylosing Spondylitis Disease Activity Score in three randomized clinical trials of ixekizumab. Rheumatology (Oxford). 2023. PMID: 36282526. doi:10.1093/rheumatology/keac618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。